Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30687798 | 0.87 | CYP2C9 (0.51) | CYP2C9CYP2C19GRM5LMNAMAPT | |
| SCHEMBL26680544 | 0.87 | CYP2C9 (0.51) | CYP2C9CYP2C19GRM5LMNAMAPT | |
| SCHEMBL1477304 | 0.86 | CYP2C9 (0.50) | CYP2C9CYP2C19GRM5LMNAACACB | |
| SCHEMBL26682935 | 0.84 | CYP2C19 (0.57) | CYP2C9CYP2C19GRM5LMNAMAPT | |
| SCHEMBL1477039 | 0.84 | MAPT (0.55) | GRM5LMNAMAPTL3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL1477229 | 0.83 | MAPT (0.54) | GRM5LMNAMAPTL3MBTL1TSHR | |
| SCHEMBL4319225 | 0.82 | ACACB (0.62) | CYP2C9CYP2C19GRM5LMNAMAPT | |
| SCHEMBL1477261 | 0.82 | CYP2C19 (0.57) | CYP2C9CYP2C19GRM5LMNAMAPT | |
| SCHEMBL4763109 | 0.81 | MAPT (0.43) | CYP2C9CYP2C19GRM5LMNAMAPT | |
| SCHEMBL3639721 | 0.81 | MEN1 (0.59) | GRM5LMNAMAPTACACBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2010078393-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | CYP2C9 4044/4885CYP2C19 2811/4885GRM5 1658/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | CYP2C9 4044/4885CYP2C19 2811/4885GRM5 1658/4885 |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | CYP2C9 1673/4885CYP2C19 2372/4885GRM5 48/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | CYP2C9 4044/4885CYP2C19 2811/4885GRM5 1658/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | CYP2C9 4462/4885CYP2C19 4301/4885GRM5 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.